Companies /Healthcare

Mckesson Corporation

NYSE: MCK Medical Distribution
$1,079.30
▼ $12.37 (−1.13%) today
Markets open · 2:29pm ET

24/7 Wall St. View

MCK at a Glance

Valuation
Market cap
$127.6B
P/E ratio
28.5
Dividend yield
0.31%
Profitability
Revenue (TTM)
$418.8B
Profit margin
1.1%
EPS (TTM)
$38.77
Price
52-week range
$722 – $1,122
24/7 target
$1,275.03
Street target
$1,144.29
Earnings
Next report
Feb 2, 2027
Q2 2027 EPS
$11.68
vs. $10.75 est.
+8.6%

Headquartered in Irving, TX Fiscal year ends March NYSE: MCK mckesson.com

About McKesson

McKesson Corporation is a diversified healthcare services company that works with biopharma companies, care providers, pharmacies, manufacturers and governments. It provides pharmaceutical distribution, specialty and oncology services, prescription technology and medical-surgical supplies. It reports four segments:
- **North American Pharmaceutical:** Drug distribution, including specialty products, to retail pharmacies, health systems and strategic accounts such as CVS Health, with a partnership extended through June 2032.
- **Oncology & Multispecialty:** Specialty distribution and provider solutions, including community oncology and the PRISM Vision Group ophthalmology network of more than 350 providers. The recently acquired Precision Medicine Group adds clinical research and biopharma commercialization services.
- **Prescription Technology Solutions:** Access solutions, third-party logistics and hub dispensing services for biopharma manufacturers.
- **Medical-Surgical Solutions:** Medical-surgical products for extended and ambulatory care. McKesson intends to separate this business into an independent company, and Apollo Funds holds an approximately 13% minority stake.

McKesson has also agreed to acquire an approximately 49% minority interest in home and community infusion provider Option Care Health. Updated

Revenue by Segment · Q2 2027
  1. North American Pharmaceutical82%
  2. Oncology & Multispecialty14%
  3. Medical-Surgical Solutions3%
  4. Prescription Technology Solutions1%

Latest Activity

MCKMcKesson
52-week high
$1105.15
+0.21%vs prior 52-week high · Nov 13, 2026

McKesson set another record high at $1,105.15, topping the mark it just made on Nov. 13. Rival Cardinal Health rose 0.97% while customer CVS Health slipped 0.82%.

Before the movelast 24 hours
  1. Jim Cramer
    We just get me into McKesson. Please. Can I just have some Amgen?
Related stockstoday
  • CAHCardinal HealthCompetitor+1.0%
    Jun 30, 2026 · SEC 10-K
  • CVSCVS HealthCustomer-0.8%
    Mar 31, 2026 · SEC 10-K
  • TAKTakeda PharmaceuticalSupplier+0.8%
    Jun 17, 6:06 AM ET · SEC 10-K

Moves: Nov 16, 2026 · Alpha Vantage daily close

5 more related stocks

MCKMcKesson
New 52-week high$1,069.02+3.8% vs prior high · 2026-10-20

McKesson cleared $1,069.02, a record 52-week high that sits 3.78% above its October 20 peak, hours after the company filed its fiscal Q2 2027 earnings.

MCKMcKesson
Q2 2027
EPS
$11.68
est $10.75+8.6%
Revenue
$110.96B
est $109.95B+0.9%

Management lifted full-year adjusted EPS guidance to $45.60 to $46.40, a fifth straight quarter of beating consensus. Specialty distribution carried it: Oncology and Multispecialty growth more than covered a profit drop in the Medical-Surgical unit being spun off.

Quarterly EPS — reported vs estimate
McKesson delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution across the enterprise.

CEO Brian Tyler's fiscal Q2 framing leans on core distribution strength, and the $124.6 billion drug wholesaler slipped slightly after he said it. With Cencora already raising its 2026 outlook on specialty momentum, the segment detail behind that "disciplined execution" is what decides whether McKesson keeps pace.

MCK -0.85%since the quote
We continue to invest strategically to advance healthcare outcomes and create long-term value. We further strengthened our portfolio through transactions that will expand our capabilities and deepen our presence in key growth areas, while maintaining our commitment to financial discipline.

Tyler is telling fiscal Q2 investors that the $124.6 billion distributor is leaning on acquisitions to push deeper into oncology and specialty care beyond basic drug distribution. The dealmaking message landed softly, with shares slightly lower since the remarks. Watch how much growth guidance rides on integrating those purchases.

MCK -0.85%since the quote
We are confident in our ability to leverage differentiated solutions and create value for customers, partners, patients, and shareholders.

Tyler's confidence line came on McKesson's fiscal 2027 second quarter call, and the $124.6 billion distributor slipped 0.85% since. Investors want specifics on oncology and biopharma services growth, so the follow-through in guidance detail is what matters here.

MCK -0.85%since the quote
MCKMcKesson
Regular session
$1065.70
+4.57%open $1019.10

A 4.57% jump to $1,065.70 adds roughly $5 billion to this $124 billion distributor, and it comes after Cencora, a competitor, filed Q4 earnings. McKesson has followed 3 of the last 4 Cencora reports with an average 4.4% move.

MCKMcKesson
New 52-week high$998.64+0.5% vs prior high · 2026-03-03

McKesson just set a fresh 52-week high at $998.64, knocking on $1,000 for the first time. The distributor has clawed back a summer drawdown that took it under $740.

Biggest movers · On the open
  • ACNAccenture$224.22+22.3%
  • SNPSSynopsys$472.79+8.7%
  • APPSDigital Turbine$11.87+6.9%
  • MCKMcKesson$904.75+6.0%
  • IBMIBM$232.95+5.9%
  • CTVACorteva$13.96-82.0%
  • NWGNatWest Group$17.54-3.4%
  • MTArcelorMittal$64.71-3.0%
  • HSBCHSBC$96.31-3.0%
  • APDAir Products & Chemicals$270.24-2.9%

Accenture opened 22% higher, a move you almost never see from a mega-cap IT services name, while Corteva dropped 82% to $13.96 at the other end of the board. Synopsys, McKesson and IBM round out a gainers list that is all up at least 5.9%.

MCK Coverage

Frequently Asked Questions

What does McKesson do?

McKesson Corporation is a diversified healthcare services company that works with biopharma companies, care providers, pharmacies, manufacturers and governments. It provides pharmaceutical distribution, specialty and oncology services, prescription technology and medical-surgical supplies.

What is the MCK stock price target?

24/7 Wall St.'s 12-month price target for MCK is $1,275.03, rated Buy. The Wall Street consensus target is $1,144.29. MCK price prediction →